Class Action Filed Against Inovio Pharmaceuticals for Securities Violations

Class Action Filed Against Inovio Pharmaceuticals

On March 26, 2026, Pomerantz LLP announced the initiation of a class action lawsuit against Inovio Pharmaceuticals, Inc., a biotechnology company renowned for its DNA medicines to combat diseases. The lawsuit, filed in the U.S. District Court for the Eastern District of Pennsylvania, is on behalf of all individuals and entities who purchased or acquired Inovio securities between October 10, 2023, and December 26, 2025. The lawsuit, documented under case number 26-cv-00803, charges Inovio and certain executives with violations of federal securities laws, specifically targeting their operations and statements made during a defined Class Period.

The accusations center on the purported damages sustained by investors who acted on the misleading information disseminated by Inovio's leadership regarding the company’s business prospects and future profitability. These alleged misrepresentations seemed to bolster investor confidence while providing a distorted view of the company’s operational realities, particularly relating to their lead product INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a severe ailment caused by Human Papillomavirus (HPV).

Inovio's corporate strategy revolved around the expectation that their product would gain FDA accelerated approval. Throughout various communications, the company's executives instilled a sense of optimism about rapidly transitioning into a commercially viable entity, indicated by the anticipated rolling submission of the INO-3107 Biologics License Application (BLA) by mid-2024. This narrative likely played a pivotal role in their funding solicitations, which raised tens of millions through security offerings within the Class Period.

However, the fabric of these assertions began unraveling when, on August 8, 2024, Inovio disclosed a delay in the anticipated BLA submission, citing manufacturing issues with its CELLECTRA device. This revelation caused an immediate impact on the company's stock, which saw a decline of 3.1%. The full scale of challenges became clearer with further disclosures in late December 2025 when the FDA accepted the INO-3107 BLA for standard review, stating that Inovio had not provided sufficient data to justify an expedited approval process. Investors reacted negatively once again, with stock dropping 24.45%. These events sparked concern and disappointment among stakeholders, marking a stark contrast to prior optimistic projections.

Pomerantz LLP, headquartered in New York and recognized as a leading firm in corporate and securities class action litigation, is committed to providing legal recourse for investors who suffered from breaches of fiduciary duty or securities fraud. The firm has a rich history of recovering substantial damages for class members, operating under the legacy of its founder Abraham L. Pomerantz, who is credited with pioneering the field of securities class actions.

Investors who acquired Inovio securities during the mentioned Class Period are encouraged to reach out by April 7, 2026, to seek designation as Lead Plaintiff in this class action. Interested parties can find complaint copies and pertinent information at www.pomerantzlaw.com. While pursuing justice for shareholders, Pomerantz LLP continues to advocate for the rights of investors facing misconduct and fraud in the securities domain.

For additional inquiries, contact Danielle Peyton at Pomerantz LLP at [email protected] or 646-581-9980, extension 7980. The firm reminds all interested investors to include their details when reaching out for clarity on their potential involvement in the case.

The unfolding of this class action against Inovio Pharmaceuticals raises significant questions about corporate accountability and transparency in biotechnology, impacting the trust and financial interests of shareholders and the overall market. As this legal process progresses, it will serve as a pivotal case study in the intersection of biotechnology, investor rights, and securities legislation.